Insider trade

Director sold ~$169K of EXEL shares in the open market

Traded Feb 13, 2026 · Filed Feb 19, 2026

Why it stands out

A board member of Exelixis sold $169K of Exelixis shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Director$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$168,854

Shares × reported transaction price

Timing vs results

3 days after results of Feb 10, 2026, 81 days before results of May 5, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+0.3%	+0.7%	−0.4%
30 days	−6.2%	−4.3%	−2.0%
90 days	+13.0%	+8.3%	+4.7%
180 days	+20.3%	+12.1%	+8.2%

Past results only. Not a forecast.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2025.
Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $42.89 to $43.89. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.
Includes 17,524 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock.